Outcomes After Discontinuation of Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia

In an interim analysis of a European trial reported in The Lancet Oncology, Saussele et al found that discontinuation of tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia (CML) with deep molecular response was associated with good molecular relapse-free survival, particularly among patients with longer major molecular response (MMR).

Breast Cancer

Risk of Interval Invasive Second Breast Cancers

In a study reported in the Journal of Clinical Oncology, Lee et al determined risk levels for interval invasive second breast cancers after negative surveillance mammography and identified factors associated with higher risk. 

Symptom Management

Planning for Potential Adverse Effects of Oral Chemotherapy

The use of oral chemotherapy drugs is becoming more and more prevalent—for many types and stages of cancer, during different treatment phases, and for varying lengths of time. So it’s vital that physicians, nurses, and advanced practitioners understand all the potential adverse events of these drugs and have monitoring and treatment plans in place to handle them when they arise. 

Cost of Care

New Laws Reduce Costs of Oral Cancer Drugs, but Not for All

The rising cost of anticancer drugs not only adds fiscal pressure to our overburdened health-care system, but also increases the stress on patients with cancer and their families. High out-of-pocket spending may cause significant financial toxicity, even for patients with good health insurance coverage. In an effort to lower the costs of certain cancer drugs, states have enacted so-called parity laws. The ASCO Post recently discussed this important issue and related topics with policy expert Stacie B. Dusetzina, PhD, Associate Professor of Health Policy and Ingram Associate Professor of Cancer Research, Vanderbilt University Medical Center, Nashville. 

Kidney Cancer

Combined Immune Checkpoint and VEGF Inhibition as First-Line Therapy in Advanced Clear Cell Kidney Cancer

In a dose-finding, dose-expansion phase Ib trial (JAVELIN Renal 100) reported in The Lancet Oncology, Toni K. Choueiri, MD, of Dana-Farber Cancer Institute and Brigham and Women’s Hospital, and colleagues determined the maximum tolerated dose of the immune checkpoint inhibitor avelumab (Bavencio) in combination with the vascular endothelial growth factor (VEGF) inhibitor axitinib (Inlyta) and found high activity of the combination in the first-line treatment of resected advanced clear cell renal cell carcinoma.1


More Top Stories

Kidney Cancer

Laurence Albiges, MD, PhD, on RCC: Results From the NIVOREN GETUG-AFU 26 Trial

Solid Tumors
Head and Neck Cancer

Lower-Dose Radiation in HPV-Positive Head and Neck Cancers After Induction Chemotherapy

The results of a phase II clinical trial suggest that patients with head and neck cancers associated with the human papillomavirus (HPV) may receive significantly lower doses of radiation safely and effectively after response to induction chemotherapy.1 These findings from the OPTIMA study,...


Childhood Cancer STAR Act Approved by Senate and House

On May 22, the Childhood Cancer Survivorship Treatment Access and Research (STAR) Act was passed by the Senate and House and is now being sent to President Donald Trump to be signed into law. As the most comprehensive childhood cancer bill ever introduced to Congress, the Childhood Cancer STAR Act...

Kidney Cancer

Daniel J. George, MD, on RCC: Results From the Alliance A031203 CABOSUN Trial

Solid Tumors
Prostate Cancer

Should We Treat Rising PSA in Men With Castrate Androgen Levels?

In rapid succession, the SPARTAN study results were presented at the 2018 Genitourinary Cancers Symposium, the data were published in The New England Journal of Medicine,1 and the drug apalutamide -(Erleada) was approved by the U.S. Food and Drug Administration (FDA) for men with previously...

Skin Cancer

Actively Recruiting Clinical Trials Focused on Nonmelanoma Skin Cancers

THE INFORMATION contained in this Clinical Trials Resource Guide includes actively recruiting clinical studies focused on nonmelanoma skin cancers—basal cell carcinoma; merkel cell carcinoma; cutaneous lymphoma; and squamous cell carcinoma. These studies are investigating brachytherapy; topical...

Treating Pediatric Glioma With Bevacizumab and Standard Treatment

Children with nonbrainstem high-grade glioma could benefit from potentially life-extending treatment if genetic testing was used to personalize therapy as it is in many adults, new research published by Mackay et al in Cancer Cell reported.  Scientists analyzed the DNA of children taking an...

Prostate Cancer

Fatima Karzai, MD, on Prostate Cancer: Treatment Study Results

Solid Tumors
Breast Cancer

Dispel Fears About Breast Cancer Radiotherapy With ‘Real Truth’ About Modern Techniques and Side Effects

Nearly 85% of patients surveyed 6 or more months after completing radiotherapy as part of their treatment for breast cancer reported the side effects were not as bad as they had feared or expected. Approximately 92% of the 269 patients treated with breast conservation and 81% of the 58 patients ...


Early Research May Unlock How Pancreatic Cancer Metastasizes to the Liver

Douglas Fearon, MD, Professor at Cold Spring Harbor Laboratory, and colleagues may have discovered how pancreatic cancer metastasizes to the liver following surgery, as reported by Pommier et al in Science. “This discovery is significant because for patients who undergo pancreatic cancer...

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.